Search
Dermatophagoides pteronyssinus
go.drugbank.com/drugs/DB10401ApprovedInvestigationalDermatophagoides pteronyssinus extracts are sterile solutions used for intradermal testing or subcutaneous immunotherapy. This combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue as a treatmen...
Mixtures: Allergenic Extract Mixture Of Standardized Mites (5,000 Au/ml), Allergenic Extract Mixture Of Standardized Mites (15,000 Au/ml)Products: Allergenic Extract Standardized Mite Dp (10,000 Au/ml), Allergenic Extract Standardized Mite Dp (30,000 Au/ml)Povidone-iodine
go.drugbank.com/drugs/DB06812ApprovedInvestigationalPovidone-iodine is a stable chemical complex of polyvinylpyrrolidone (povidone, PVP) and elemental iodine. It contains from 9.0% to 12.0% available iodine, calculated on a dry basis. This unique complex was discovered in 1955 at the Indu...
Mixtures: Physicians EZ Use M-pred, Physicians EZ Use M-predProducts: JOD POLYVID WUND U BRA I P, Bd E-Z ScrubPibrentasvir
go.drugbank.com/drugs/DB13878ApprovedInvestigationalthe emergence of amino acid substitutions at known NS5A inhibitor resistance-associated positions in HCV genotype 1a, 2a or 3a replicons led to reduced susceptibility and resistance to pibrentasvir [FDA … This fixed-dose combination therapy was FDA-approved in August 2017 to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including
Aducanumab
go.drugbank.com/drugs/DB12274ApprovedInvestigationalthe data [A235720] and aducanumab was granted accelerated FDA approval on 7 June 2021. … [A235720] Development of aducanumab was discontinued in March 2019 when two phase 3 clinical trials did not pass futility analysis; however, Biogen sought FDA approval in October 2019 after reanalyzing
Gemtuzumab ozogamicin
go.drugbank.com/drugs/DB00056ApprovedInvestigationalGemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody [FDA Label]. … Marketing approval of gemtuzumab ozogamicin was granted on May 17, 2000 by FDA as a treatment for patients with CD33-positive AML in first relapse who are 60 years of age or older and who are not considered
Teplizumab
go.drugbank.com/drugs/DB06606ApprovedInvestigational[A241480] On November 2022, teplizumab was approved by the FDA as the first drug that can delay the onset of type 1 diabetes. … [L44096] In April 2026, the FDA approved an expanded indication for teplizumab, lowering the eligible age range from 8 years and older down to 1 year and older for patients with Stage 2 T1D.[L56140]
Vericiguat
go.drugbank.com/drugs/DB15456ApprovedInvestigational[L31178] Vericiguat was approved by the FDA in January 2021 - developed by Merck under the brand name Verquvo - for use in certain patients with systolic heart failure. … [L31178] Although not the first sGC stimulator to be granted FDA approval ([riociguat] was approved in 2013 for use in pulmonary hypertension),[L3955] vericiguat is unique amongst its peers in that modifications
Selumetinib
go.drugbank.com/drugs/DB11689ApprovedInvestigationalMost recently, on November 20, 2025, the FDA expanded this indication to include adults [L53881] … [A193533] Following its initial FDA approval on April 10, 2020,[L49991] and Health Canada approval on August 23, 2022,[L49986] the regulatory landscape has evolved.
Dabrafenib
go.drugbank.com/drugs/DB08912ApprovedInvestigationalDabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic n...
Revakinagene taroretcel
go.drugbank.com/drugs/DB05344ApprovedInvestigational[A265115] On March 6, 2025, FDA approved revakinagene taroretcel for the treatment of idiopathic macular telangiectasia type 2.